Amprion Honored to Win the 2024 BioTech Breakthrough Award ‘Clinical Diagnostics Solution of the Year’

Amprion’s Award-Winning SAAmplify-ɑSYN Assay Helps Diagnose a Variety of Neurodegenerative Conditions

Amprion Co-Founder, Dr. Claudio Soto, Awarded Michael J. Fox Foundation’s Robert A. Pritzker Prize for Leadership in Parkinson's Research

Amprion, a global leader advancing diagnoses of neurodegenerative disorders, is closing out 2024 with several prestigious awards. Its novel assay, SAAmplify™-ɑSYN, won ‘Clinical Diagnostics Solution of the Year’ through the Biotech Breakthrough Awards Program. The Michael J. Fox Foundation (MJFF) also awarded Amprion’s co-founder, Dr. Claudio Soto, with ‘The Robert A. Pritzker Prize for Leadership in Parkinson's Research.’

Amprion’s SAAmplify-ɑSYN (formerly SYNTap®) biomarker test is the only validated seed amplification assay available to help diagnose synucleinopathies associated with Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with neocortical Lewy body co-pathology. The breakthrough assay was selected out of thousands of nominations to win ‘Clinical Diagnostics Solution of the Year.’ A recently issued Letter of Support from the FDA recommending the use of αSYN SAA for research and clinical trials further reinforces its impact and utility.

“These awards represent a collective dedication to uncovering the mysteries of the human brain,” said Russell Lebovitz, MD, PhD, CEO and co-founder of Amprion. “Amprion’s mission is to build a future where early diagnosis and intervention are not just possibilities, but realities. It is an honor to have the opportunity to further advance the field and bring hope to patients and their loved ones.”

Dr. Soto’s early work on misfolded protein amplification laid the groundwork for alpha-synuclein seed amplification assays, like SAAmplify-ɑSYN. His work and dedication to advancing better treatments for Parkinson's patients earned him the MJFF annual Robert A. Pritzker Prize.

Amprion recently secured $6M in a successful Series B fundraise led by Formation Venture Engineering, Eli Lilly, and Amprion’s Series A investors. The funds are being used to expand Amprion’s commercial strategy, as the company continues to partner with pharma companies to develop therapies for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.

To learn more about Amprion or SAAmplify-ɑSYN, visit ampriondx.com.

About SAAmplify-ɑSYN (formerly SYNTap®)

Amprion's SAAmplify-ɑSYN Biomarker Test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer's disease (AD) with neocortical Lewy body co-pathology. The U.S. Food and Drug Administration (FDA) granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in the diagnosis of PD. SYNTap became commercially available in 2021.

About Amprion

Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion’s intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. The SAAmplify-ɑSYN biomarker test (formerly SYNTap) is the only seed amplification assay available to aid the diagnosis of synucleinopathies associated with Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with Lewy body copathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at https://ampriondx.com/ or find us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241119785149/en/